Syntec Optics Secures $4.6 Million Order for Advanced Laser Blood-Test Cartridges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: Newsfilter
- Significant Order Value: Syntec Optics announced a $4.6 million purchase order for the continued manufacturing of advanced laser blood-test cartridges and optical reader subsystems, which will provide critical medical equipment to global clinics and hospitals, ensuring a stable revenue stream in the biomedical sector.
- Enhanced Production Capacity: The company's disposable point-of-care cartridges are widely used in clinical laboratories worldwide, enabling up to 750 tests simultaneously in high-demand areas such as ICUs, significantly improving hospital testing efficiency and meeting urgent diagnostic needs.
- Technological Innovation in Crisis: During the COVID-19 pandemic, Syntec's biomedical product line demonstrated robust production capabilities, providing real-time blood gas analysis at critical moments, which helped healthcare providers make swift decisions and improved patient survival rates.
- Future Growth Potential: With ongoing advancements in optical technology, Syntec Optics plans to expand its product lines to include low Earth orbit satellite optics and AI-driven AR/VR systems, which are expected to further enhance the company's market share and technological leadership in the optics and photonics industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPTX
About OPTX
Syntec Optics Holdings, Inc. is a custom optics and photonics manufacturer in the United States. The Company offers optics and photonics components and sub-systems from opto-mechanicals to optical elements of various geometries, diamond turned optics for both prototype and production, and optical systems including optics assembly, electro-optics assembly, design, and coating. It offers a range of services to support its manufacturing capabilities, including tool design, design for manufacturing, optical and opto-mechanical design, and mold flow analysis. It offers single point diamond turning for prototyped polymer optics and its patented high refraction diamond. It integrates mold and tooling development to align with the total need for design, production and assembly. It offers conventional mold manufacturing and design services, using 3D modeling software, CNC lathes, milling and grinding machines. It also offers satellite optics and optomechanical solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Syntec Optics Secures $4.6 Million Order for Advanced Laser Blood-Test Cartridges
- Significant Order Value: Syntec Optics announced a $4.6 million purchase order for the continued manufacturing of advanced laser blood-test cartridges and optical reader subsystems, which will provide critical medical equipment to global clinics and hospitals, ensuring a stable revenue stream in the biomedical sector.
- Enhanced Production Capacity: The company's disposable point-of-care cartridges are widely used in clinical laboratories worldwide, enabling up to 750 tests simultaneously in high-demand areas such as ICUs, significantly improving hospital testing efficiency and meeting urgent diagnostic needs.
- Technological Innovation in Crisis: During the COVID-19 pandemic, Syntec's biomedical product line demonstrated robust production capabilities, providing real-time blood gas analysis at critical moments, which helped healthcare providers make swift decisions and improved patient survival rates.
- Future Growth Potential: With ongoing advancements in optical technology, Syntec Optics plans to expand its product lines to include low Earth orbit satellite optics and AI-driven AR/VR systems, which are expected to further enhance the company's market share and technological leadership in the optics and photonics industry.
See More
Albert A. Manzone Appointed Interim CEO Following Lockwood-Taylor's Resignation
- Leadership Transition: Perrigo Company has appointed Albert A. Manzone as Interim CEO effective immediately following Patrick Lockwood-Taylor's resignation due to personal conduct deemed inconsistent with the company's values, although this conduct did not affect business operations or financial reporting.
- Board Confidence: The Board expresses full confidence in Manzone's leadership capabilities, citing his 30 years of global experience and business transformation expertise as critical for maintaining strategic stability during this transition and continuing value creation.
- 2026 Outlook Reaffirmed: Perrigo reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, and adjusted EPS of $2.00 to $2.30, indicating clarity in financial goals despite the leadership change.
- Manzone's Priorities: As Interim CEO, Manzone emphasizes continuity of the company's strategy and support for the leadership team to sustain momentum in value creation, demonstrating his commitment to the company's future growth.
See More
Perrigo Appoints Interim CEO Following Resignation
- Leadership Change: Perrigo's Board has appointed Albert A. Manzone as Interim CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues, highlighting the company's commitment to leadership standards.
- Strategic Continuity: As Interim CEO, Manzone pledges to maintain the company's strategic direction and momentum in value creation, reflecting confidence in the company's future despite leadership changes.
- Reaffirmed Performance Outlook: Perrigo has reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, indicating stability in financial expectations amid leadership transitions.
- Extensive Leadership Experience: With over 30 years of global leadership experience across various industries, Manzone is expected to bring fresh perspectives and opportunities for value creation to Perrigo.
See More
Starfighters Space Joins Russell 3000 Index, Signaling Growth
- Rapid Growth Milestone: Starfighters Space, Inc. has achieved a significant milestone by joining the Russell 3000 Index just seven months after its December 2025 IPO, indicating a swift increase in market recognition that is expected to attract more institutional investor interest.
- Importance of Market Capitalization: Membership in the Russell 3000 Index is based on objective market capitalization rankings, meaning that Starfighters Space's inclusion will enhance its visibility within the $12.2 trillion asset benchmark, thereby improving its trading liquidity.
- Innovative Launch Platform: The company is developing the STARLAUNCH airborne launch platform, utilizing its F-104 supersonic aircraft for efficient payload launches, which offers customers greater responsiveness and reusability, catering to commercial and defense needs.
- Leading Industry Trends: By joining the Russell 3000 Index alongside other emerging space and defense companies, Starfighters Space's unique business model and technological innovations position it to stand out in the competitive landscape, marking the rise of small space companies and the expansion of the market.
See More
Syntec Optics Q1 Financial Results and Stock Offering
- Financial Performance: Syntec Optics reported a Q1 GAAP EPS of -$0.02 and revenue of $6.5 million, reflecting an 8.5% year-over-year decline, indicating pressure in market competitiveness that could affect investor confidence moving forward.
- Stock Offering: The company successfully priced a $20 million stock offering at $7 per share, aimed at enhancing liquidity and supporting future business expansion, despite the current underwhelming financial performance.
- Defense Orders: Syntec secured $4 million in defense orders, leading to a stock price increase of over 6%, suggesting strong demand in specific market segments that may bolster future revenue growth.
- Market Reaction: Although the Q1 financial data is disappointing, the positive news from the stock offering and defense orders may improve market sentiment in the short term, helping the company maintain stability in a competitive environment.
See More
Syntec Optics Reports Q1 2026 Financial Results Amid Shipment Delays
- Revenue Decline: Q1 2026 revenue was $6.5 million, down from $7.1 million in Q1 2025, primarily due to temporary shipment delays in the biomedical market, which adversely affected overall performance.
- Gross Profit Reduction: Gross profit for Q1 2026 was $1.0 million, significantly lower than $2.3 million in Q1 2025, with gross margin impacted by reduced production volume and holiday shutdowns leading to higher fixed manufacturing overhead absorption rates.
- Increased Net Loss: The net loss for Q1 2026 was approximately $0.9 million, or $(0.02) per diluted share, compared to a net income of $0.3 million in Q1 2025, reflecting the negative impacts of shipment delays and holiday shutdowns.
- Capital Structure Optimization: The company successfully completed a public offering, raising approximately $21.5 million in net proceeds, significantly enhancing liquidity and paying down its revolving credit balance to zero, thereby providing funding support for future growth opportunities.
See More
Syntec Optics Secures $4.6 Million Order for Advanced Laser Blood-Test Cartridges
- Significant Order Value: Syntec Optics announced a $4.6 million purchase order for the continued manufacturing of advanced laser blood-test cartridges and optical reader subsystems, which will provide critical medical equipment to global clinics and hospitals, ensuring a stable revenue stream in the biomedical sector.
- Enhanced Production Capacity: The company's disposable point-of-care cartridges are widely used in clinical laboratories worldwide, enabling up to 750 tests simultaneously in high-demand areas such as ICUs, significantly improving hospital testing efficiency and meeting urgent diagnostic needs.
- Technological Innovation in Crisis: During the COVID-19 pandemic, Syntec's biomedical product line demonstrated robust production capabilities, providing real-time blood gas analysis at critical moments, which helped healthcare providers make swift decisions and improved patient survival rates.
- Future Growth Potential: With ongoing advancements in optical technology, Syntec Optics plans to expand its product lines to include low Earth orbit satellite optics and AI-driven AR/VR systems, which are expected to further enhance the company's market share and technological leadership in the optics and photonics industry.
See More
Albert A. Manzone Appointed Interim CEO Following Lockwood-Taylor's Resignation
- Leadership Transition: Perrigo Company has appointed Albert A. Manzone as Interim CEO effective immediately following Patrick Lockwood-Taylor's resignation due to personal conduct deemed inconsistent with the company's values, although this conduct did not affect business operations or financial reporting.
- Board Confidence: The Board expresses full confidence in Manzone's leadership capabilities, citing his 30 years of global experience and business transformation expertise as critical for maintaining strategic stability during this transition and continuing value creation.
- 2026 Outlook Reaffirmed: Perrigo reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, and adjusted EPS of $2.00 to $2.30, indicating clarity in financial goals despite the leadership change.
- Manzone's Priorities: As Interim CEO, Manzone emphasizes continuity of the company's strategy and support for the leadership team to sustain momentum in value creation, demonstrating his commitment to the company's future growth.
See More
Perrigo Appoints Interim CEO Following Resignation
- Leadership Change: Perrigo's Board has appointed Albert A. Manzone as Interim CEO following the resignation of Patrick Lockwood-Taylor due to personal conduct issues, highlighting the company's commitment to leadership standards.
- Strategic Continuity: As Interim CEO, Manzone pledges to maintain the company's strategic direction and momentum in value creation, reflecting confidence in the company's future despite leadership changes.
- Reaffirmed Performance Outlook: Perrigo has reaffirmed its 2026 financial outlook, projecting net sales growth between -5.5% and -1.5%, indicating stability in financial expectations amid leadership transitions.
- Extensive Leadership Experience: With over 30 years of global leadership experience across various industries, Manzone is expected to bring fresh perspectives and opportunities for value creation to Perrigo.
See More
Starfighters Space Joins Russell 3000 Index, Signaling Growth
- Rapid Growth Milestone: Starfighters Space, Inc. has achieved a significant milestone by joining the Russell 3000 Index just seven months after its December 2025 IPO, indicating a swift increase in market recognition that is expected to attract more institutional investor interest.
- Importance of Market Capitalization: Membership in the Russell 3000 Index is based on objective market capitalization rankings, meaning that Starfighters Space's inclusion will enhance its visibility within the $12.2 trillion asset benchmark, thereby improving its trading liquidity.
- Innovative Launch Platform: The company is developing the STARLAUNCH airborne launch platform, utilizing its F-104 supersonic aircraft for efficient payload launches, which offers customers greater responsiveness and reusability, catering to commercial and defense needs.
- Leading Industry Trends: By joining the Russell 3000 Index alongside other emerging space and defense companies, Starfighters Space's unique business model and technological innovations position it to stand out in the competitive landscape, marking the rise of small space companies and the expansion of the market.
See More
Syntec Optics Q1 Financial Results and Stock Offering
- Financial Performance: Syntec Optics reported a Q1 GAAP EPS of -$0.02 and revenue of $6.5 million, reflecting an 8.5% year-over-year decline, indicating pressure in market competitiveness that could affect investor confidence moving forward.
- Stock Offering: The company successfully priced a $20 million stock offering at $7 per share, aimed at enhancing liquidity and supporting future business expansion, despite the current underwhelming financial performance.
- Defense Orders: Syntec secured $4 million in defense orders, leading to a stock price increase of over 6%, suggesting strong demand in specific market segments that may bolster future revenue growth.
- Market Reaction: Although the Q1 financial data is disappointing, the positive news from the stock offering and defense orders may improve market sentiment in the short term, helping the company maintain stability in a competitive environment.
See More
Syntec Optics Reports Q1 2026 Financial Results Amid Shipment Delays
- Revenue Decline: Q1 2026 revenue was $6.5 million, down from $7.1 million in Q1 2025, primarily due to temporary shipment delays in the biomedical market, which adversely affected overall performance.
- Gross Profit Reduction: Gross profit for Q1 2026 was $1.0 million, significantly lower than $2.3 million in Q1 2025, with gross margin impacted by reduced production volume and holiday shutdowns leading to higher fixed manufacturing overhead absorption rates.
- Increased Net Loss: The net loss for Q1 2026 was approximately $0.9 million, or $(0.02) per diluted share, compared to a net income of $0.3 million in Q1 2025, reflecting the negative impacts of shipment delays and holiday shutdowns.
- Capital Structure Optimization: The company successfully completed a public offering, raising approximately $21.5 million in net proceeds, significantly enhancing liquidity and paying down its revolving credit balance to zero, thereby providing funding support for future growth opportunities.
See More
